Literature DB >> 26743781

Bilaterality weighs more than unilateral multifocality in predicting prognosis in papillary thyroid cancer.

Ning Qu1,2, Ling Zhang1,2, Wei-Li Wu3, Qing-Hai Ji4,5, Zhong-Wu Lu1,2, Yong-Xue Zhu1,2, Dao-Zhe Lin3.   

Abstract

Papillary thyroid cancer (PTC) often presents as multifocal tumor;, however, whether multifocality is associated with poor prognosis remains controversial. The aims of this retrospective study were to identify the characteristics of PTC with multifocal tumors and evaluate the association between the location and prognosis. We reviewed the medical records of 496 patients who underwent total thyroidectomy for PTC. Patients were classified as three groups: N1 (solitary tumor), N2 (2 or more foci within unilateral lobe of thyroid), and N3 (bilateral tumors, at least one tumor focus for each lobe of thyroid). We analyzed the differences of clinicopathologic features and clinical outcomes among the three groups. Cox regression model was used to assess the relation between the different locations of multifocal tumors and prognosis. Although the differences of clinicopathologic features such as the size of tumor, extrathyroidal extension, and cervical lymph node metastasis were not significant among the three groups, the bilateral-multifocality was proved to be an independent risk factor for neck recurrence (hazard ratio (HR) = 4.052, 95 % confidence interval (CI) 2.070-7.933), distant metastasis (HR = 3.860, 95 % CI 1.507-9.884), and cancer death (HR = 7.252, 95 % 2.189-24.025). In addition, extrathyroidal extension (HR = 2.291, 95 % CI 1.185-4.427) and older age >45 years (HR = 6.721, 95 % CI 2.300-19.637) were also significant predictors for neck recurrence and cancer death, respectively. Therefore, bilateral-multifocality as an indicator for more extensive tumor location could be used to assess the risk of recurrence and mortality in PTC. Given the poor prognosis associated with bilateral-multifocality and other risk factors, aggressive therapy and intensive follow-up were recommended for PTC patients with them.

Entities:  

Keywords:  Bilaterality; Multifocality; Papillary thyroid cancer; Prognosis

Mesh:

Year:  2016        PMID: 26743781     DOI: 10.1007/s13277-015-4533-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  Multistate life-tables and regression models.

Authors:  R D Gill
Journal:  Math Popul Stud       Date:  1992       Impact factor: 0.720

2.  Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients.

Authors:  Ling Zhang; Wen-Jun Wei; Qing-Hai Ji; Yong-Xue Zhu; Zhuo-Ying Wang; Yu Wang; Cai-Ping Huang; Qiang Shen; Duan-Shu Li; Yi Wu
Journal:  J Clin Endocrinol Metab       Date:  2012-02-08       Impact factor: 5.958

3.  Number of tumor foci as predictor of lateral lymph node metastasis in papillary thyroid carcinoma.

Authors:  Hye Jeong Kim; Hyeong Kyu Park; Dong Won Byun; Kyoil Suh; Myung Hi Yoo; Yong-Ki Min; Sun Wook Kim; Jae Hoon Chung
Journal:  Head Neck       Date:  2014-04-10       Impact factor: 3.147

4.  Nonparametric estimation of lifetime and disease onset distributions from incomplete observations.

Authors:  G E Dinse; S W Lagakos
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

5.  Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma.

Authors:  Qunzi Zhao; Jie Ming; Chunping Liu; Lan Shi; Xia Xu; Xiu Nie; Tao Huang
Journal:  Ann Surg Oncol       Date:  2012-09-13       Impact factor: 5.344

6.  Clinical implication of the number of central lymph node metastasis in papillary thyroid carcinoma: preliminary report.

Authors:  Yoon Se Lee; Yun Sung Lim; Jin-Choon Lee; Soo-Geun Wang; In-Ju Kim; Byung-Joo Lee
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

7.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

8.  High recurrent rate of multicentric papillary thyroid carcinoma.

Authors:  Jen-Der Lin; Tzu-Chieh Chao; Chuen Hsueh; Sheng-Fong Kuo
Journal:  Ann Surg Oncol       Date:  2009-06-16       Impact factor: 5.344

9.  Occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma.

Authors:  Bon Seok Koo; Hyun Sil Lim; Young Chang Lim; Yeo-Hoon Yoon; Yong Min Kim; Yong Ho Park; Ki-Sang Rha
Journal:  Ann Surg Oncol       Date:  2010-04       Impact factor: 5.344

10.  Prognosis of multifocal papillary thyroid carcinoma.

Authors:  Sheng-Fong Kuo; Shu-Fu Lin; Tzu-Chieh Chao; Chuen Hsueh; Kun-Ju Lin; Jen-Der Lin
Journal:  Int J Endocrinol       Date:  2013-12-30       Impact factor: 3.257

View more
  11 in total

1.  The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.

Authors:  Fei Wang; Xiaolong Yu; Xiaopei Shen; Guangwu Zhu; Yueye Huang; Rengyun Liu; David Viola; Rossella Elisei; Efisio Puxeddu; Laura Fugazzola; Carla Colombo; Barbara Jarzab; Agnieszka Czarniecka; Alfred K Lam; Caterina Mian; Federica Vianello; Linwah Yip; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Bela Bendlova; Vlasta Sýkorová; Yangang Wang; Shiguo Liu; Jiajun Zhao; Shihua Zhao; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

2.  Multifocality and Progression of Papillary Thyroid Microcarcinoma During Active Surveillance.

Authors:  Ryuta Nagaoka; Aya Ebina; Kazuhisa Toda; Tomoo Jikuzono; Marie Saitou; Masaomi Sen; Hiroko Kazusaka; Mami Matsui; Keiko Yamada; Hiroki Mitani; Iwao Sugitani
Journal:  World J Surg       Date:  2021-06-07       Impact factor: 3.352

3.  Prognostic significance of the sum of the diameters of single foci in multifocal papillary thyroid cancer: the concept of new-old tumor burden.

Authors:  Jacopo Manso; Simona Censi; Amir Roberti; Maurizio Iacobone; Susi Barollo; Loris Bertazza; Francesca Galuppini; Federica Vianello; Nora Albinger; Carla Scaroni; Gianmaria Pennelli; Caterina Mian
Journal:  Ther Adv Endocrinol Metab       Date:  2020-10-12       Impact factor: 3.565

4.  A Rare Case of Multifocal Papillary Thyroid Cancer in Bilateral Thyroid Cysts.

Authors:  Anupama Roy Chowdhury; Jack Kian Ch'ng; Choon Chieh Tan
Journal:  Case Rep Med       Date:  2018-04-17

5.  Identifying risk factors for recurrence of papillary thyroid cancer in patients who underwent modified radical neck dissection.

Authors:  Young Jae Ryu; Jin Seong Cho; Jung Han Yoon; Min Ho Park
Journal:  World J Surg Oncol       Date:  2018-10-12       Impact factor: 2.754

6.  Risk of needing completion thyroidectomy for low-risk papillary thyroid cancers treated by lobectomy.

Authors:  A N DiMarco; M S Wong; J Jayasekara; D Cole-Clark; A Aniss; A R Glover; L W Delbridge; M S Sywak; S B Sidhu
Journal:  BJS Open       Date:  2019-02-06

7.  Clinical Study of Virtual Reality Augmented Technology Combined with Contrast-Enhanced Ultrasound in the Assessment of Thyroid Cancer.

Authors:  Qinghua Liu; Jian Cheng; Jingjing Li; Lei Liu; Hongbo Li
Journal:  J Healthc Eng       Date:  2021-08-06       Impact factor: 2.682

8.  Real-Time Elastography: A Web-Based Nomogram Improves the Preoperative Prediction of Central Lymph Node Metastasis in cN0 PTC.

Authors:  Chunwang Huang; Wenxiao Yan; Shumei Zhang; Yanping Wu; Hantao Guo; Kunming Liang; Wuzheng Xia; Shuzhen Cong
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

9.  The Differences Between Multifocal and Unifocal Papillary Thyroid Carcinoma in Unilateral Lobe: A Meta-Analysis.

Authors:  Ting Zhang; Liang He; Zhihong Wang; Wenwu Dong; Wei Sun; Ping Zhang; Hao Zhang
Journal:  Front Oncol       Date:  2021-09-16       Impact factor: 6.244

Review 10.  Clinical outcomes of multifocal papillary thyroid cancer: A systematic review and meta-analysis.

Authors:  Likun Cui; Dongdong Feng; Chaofan Zhu; Qiuyu Li; Wenqing Li; Baoguo Liu
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.